Clinical Trial Update: Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating alternating regimens of Sacituzumab govitecan and Trastuzumab deruxtecan in patients with metastatic or locally advanced …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Low-expressing Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)
• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: UNICANCER | Conditions: Triple Negative Breast Neoplasms, Neoplasm Metastasis | Phase 2 | Status: NOT_YET_RECRUITING